KR101416140B1 - Topical Composition For Promoting Lipid Biosynthesis Comprising Ginsenosides Rg3 As Active Ingredient - Google Patents

Abstract

The present invention relates to a composition for external application for skin containing ginsenoside Rg3 as an active ingredient. The composition for external application for skin of the present invention can be used for promoting biosynthesis of triglyceride, cholesterol or ceramide by controlling the transcription factors of sterol regulatory factor binding protein (SREBP-1c), peroxisome proliferation-activating receptors (PPARs) Thereby maintaining skin homeostasis and preventing skin aging.

Description

(Topical Composition For Promoting Lipid Biosynthesis Comprising Ginsenosides Rg3 As Active Ingredient) which contains ginsenoside Rg3 as an active ingredient,

The present invention relates to a composition for external application for skin containing ginsenoside Rg3 as an active ingredient.

The lipids that make up the skin barrier are composed of sebaceous lipid and epidermal lipid, which are produced in Sebocyte and keratinocyte, respectively. Sebum produced in Sebocyte is secreted through hair follicle and lipid produced in keratinocyte is stored in the lamellar body of S. spinosum and S.granulosum, Respectively. There are about one million sebaceous glands in the human body, and they are mainly in the face, head, breast, armpit, navel, and neck. The sebaceous gland is a holocrine gland that secretes sebum by the stem of hair and is known to secrete about 2g per day. The ingredients of sebum are known as triglyceride, free fatty acid, wax ester, squalene, cholesteryl ester, cholesterol and the like. The sebaceous glands are responsible for the regulation of cutaneous steroidogenesis, the regulation of local androgen synthesis, the interaction of neuropeptides, lipid production with antimicrobial activity, pro-inflammatory properties, And is responsible for the expression of anti-inflammatory properties. The keratinocyte lipid is composed of cholesterol, fatty acid, ceramide, and sphingolipid, and exists in a lamellar structure. In addition, ceramide is known to contain 50% of the intercellular lipid in the structure with the hydroxy group attached to the backbone composed of sphingosine, phytosphingosine and 6-hydroxysingin.

The distribution ratios and the mass of these compositions contribute to skin barrier homeostasis and provide a quick resilience to external physical and chemical damage. The epidermal lipid in the aging process, unlike the epidermal tissue, is generally reduced and the function of the skin barrier is deteriorated.

In addition, the total epidermal lipid content of elderly people is reduced to about 30% of the younger age, but the ratio of each lipid content is maintained.

It has been reported in the literature that lipids of the skin keratin are formed through the lipid biosynthetic pathway and the ceramide biosynthesis pathway and actually lipids of the skin horn are derived from phospholipids and free fatty acids of the dermis [Hamanaka et al., 2002 , J. Invsti. Dermatol. 119: 416-423. It is also known that as the ratio of free fatty acids changes, it can progress to aging skin [Rogers et al., 1996, Arch. Dermatol. Res., 288: 765-770).

Ginsenoside Rg3 is a saponin in ginseng that is chemically called a glycoside. Saponin is derived from the saponin of the Greek word for soap, which is a name given to making fine bubbles like soap in aqueous solution. Saponin is known to be a non-nutrient in the roots, stems, leaves, husks, and seeds of plants. However, recently saponins have become known as physiologically active substances because of their anticancer, antioxidant and cholesterol lowering effects. Saponin is the main pharmacological agent among various active ingredients of ginseng.

Ginseng saponin has a unique chemical structure that is different from saponin found in other plants. Its pharmacological efficacy is also unique and is called 'Ginsenoside' in the sense of Ginseng Glycoside. The chemical structure of ginsenoside Rg3 is shown in Fig.

The inventors of the present invention have studied the applicability of various natural products to cosmetics. As a result, Rg3, a kind of ginsenoside, is known as sterol regulatory element-binding proteins (SREBP-1c) ), Peroxisome proliferator-activated receptors (hereinafter referred to as PPARs), and fatty acid synthase (hereinafter referred to as 'FAS') to promote the biosynthesis of intercellular proteins The present invention aims to maintain the skin barrier effect of the epidermis and to maintain the homeostasis-maintaining function and anti-aging function of the whole skin by treating and preventing the lipid homeostasis of the skin epidermal layer caused by aging and the like.

Therefore, the object of the present invention as described above is achieved by a composition containing Rg3, which is a kind of ginsenoside, as an active ingredient. The composition has a skin homeostasis-maintaining effect and an anti-aging effect by increasing skin lipid biosynthesis

Preferably, the composition is characterized by promoting transcription factors of sterol regulatory factor binding protein (SREBP-1c), peroxisome proliferation-activating receptors (PPARs) and fatty acid synthetase (FAS) to increase skin lipid biosynthesis do.

Also preferably, the composition is characterized in that it increases the amount of cholesterol, ceramide or triglyceride expression to increase skin lipid biosynthesis.

Preferably, Rg3 is contained in an amount of 0.000001 to 40.0% by weight based on the total weight of the composition.

Also preferably, the composition is in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, cleansing oil, powder foundation, emulsion foundation, wax foundation, pack, massage cream and spray Lt; RTI ID = 0.0 > formulations < / RTI >

The ginsenoside Rg3 according to the present invention has an effect of increasing the expression of SREBP-1c, PPARs and FAS, increasing lipid through nile red staining & flow cytometry, increasing cholesterol expression, increasing triglyceride expression, and increasing ceramide expression.

Figure 1 shows the structural formula of ginsenoside Rg3.
Figure 2 shows lipid production when keratinocytes were coated with Rg3 and linolenic acid.

The present invention relates to a composition for promoting biosynthesis of a skin epidermal lipid. The present invention relates to a composition for external application for skin containing ginsenoside Rg3 as an active ingredient, which maintains skin homeostasis by increasing lipid biosynthesis. The composition can be used to increase the biosynthesis of triglyceride, cholesterol or ceramide by controlling the transcription factors of sterol regulatory factor binding protein (SREBP-1c), peroxisome proliferation-activating receptors (PPARs) or fatty acid synthetase (FAS) To treat and prevent the disruption of the homeostasis of skin epidermal lipids due to lipid degradation such as ceramide.

It is obvious to those skilled in the art that the ginsenoside Rg3 used in the present invention can be isolated from ginseng but chemically synthesized can also exhibit the same effect. The ginsenoside Rg3 can be obtained by adding or substituting a substituent It is apparent to those skilled in the art in view of the state of the art that derivatives obtained by the reaction are also included in the scope of the present invention.

Hereinafter, a method for producing ginsenoside Rg3 will be described with reference to the following specific production examples of the present invention. The ginseng is washed with purified water, dried and crushed into small pieces, Of lower alcohol is added. It is extracted at a constant temperature for a certain period, filtered, and then dried with a rotary evaporator. Separate ginsenoside Rg3 from dried ginseng extract powder using prep LC.

According to the present invention, Rg3 is contained in an amount of 0.000001 to 40.0 wt% with respect to the total weight of the composition, and more preferably, Rg3 is contained in an amount of 0.001 to 10 wt% with respect to the total weight of the composition. When the content of the extract is less than 0.000001% by weight, no effective effect is exhibited. When the content of the extract is more than 40.0% by weight, the improvement effect on the increase of the content is insignificant and there is a problem in safety and stability of the form and is not economical .

The composition of the present invention including Rg3 is characterized by having an effect of increasing the expression of SREBP-1c, PPARs, FAS, increasing lipid, increasing cholesterol, increasing ceramide expression, and increasing triglyceride expression.

The components included in the composition of the present invention may contain, in addition to the above-mentioned effective components, the components conventionally used in the composition for external application for skin, such as conventional adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, Carrier.

In case of applying to medicines, an oral or parenteral administration can be carried out in the form of a solid, semi-solid or liquid form by adding an inorganic or organic carrier which is used as an active ingredient of ginsenoside Rg3 according to the present invention.

Examples of the agent for oral administration include tablets, pills, tablets, soft capsules, powders, fine granules, powders, emulsions, syrups, fillets and the like. For parenteral administration, injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like may be mentioned. In order to formulate the active ingredient of the present invention, it can be easily formulated according to a conventional method. Surfactants, excipients, coloring agents, spices, preservatives, stabilizers, buffers, suspending agents and other adjuvants for commercialization can be suitably used.

The compositions of the present invention may be prepared in any of the formulations conventionally manufactured in the art and may be in the form of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, Oil, powder foundation, emulsion foundation, wax foundation, pack, massage cream and spray, but are not limited thereto. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.

When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .

When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.

In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.

When the formulation of the present invention is a surfactant-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether Alkylamido betaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester.

When the composition of the present invention is a soap, a surfactant-containing cleansing formulation or a surfactant-free cleansing formulation, it may be applied to the skin and then wiped off, washed or rinsed with water. The surfactant-containing cleansing formulation may be a cleansing foam, a cleansing water, a cleansing towel and a cleansing pack. The surfactant-free cleansing formulation may be a cleansing cream, , Cleansing lotion, cleansing water and cleansing gel, but is not limited thereto.

The composition of the present invention may be used alone or in combination, or may be used in combination with other compositions than the present invention. In addition, the composition according to the present invention can be used according to a conventional method of use, and the number of times of use may be varied depending on the skin condition or taste of the user.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .

Production Example 1: Production of ginsenoside Rg3

The method for producing ginsenoside Rg3 used in the present invention is as follows.

The ginseng is washed with purified water, dried and crushed into small pieces, and then 70% lower alcohol of 1-10 times its dry weight is added. The mixture was extracted at 15-35 ° C for 5 days, filtered through a 300-mesh filter cloth, filtered through filter paper No. 5, and dried with a rotary evaporator to obtain a dry weight of 30.4 g. Ginsenoside Rg3 was isolated from dried Ginseng Extract Powder using Purge ELISA (Waters Co., Ltd., Delta prep 4000, USA).

Production Example 2: Preparation of ginsenoside Rg3

6 g of ginseng crude saponin prepared by a conventional method for isolating an extract extracted from ginseng or red ginseng as an alcohol extraction solvent was dissolved in 20 ml of 50% acetic acid and heated for 2 hours at 70 캜 with stirring, . The reaction solution was diluted with 200 ml of distilled water and extracted three times with 100 ml of n-butanol. The combined extracts were washed twice with saturated sodium bicarbonate solution and the n-butanol layer was concentrated under reduced pressure. The reaction mixture was separated into silica gel column grommetography (chloroform: ethanol: water = 100: 30: 10, lower layer) to obtain ginsenoside Rg3.

Experimental Example 1: Cell culture

The cells used in the experimental examples were cultured in the following manner.

① Keratinocyte: Keratinocyte

Human normal skin cells, keratinocytes (Korean Cell Line Bank, Korea), were inoculated into 48-well microplates (Nunc, Denmark) at a density of 1 × 10 ⁶ cells per well. DMEM medium (Sigma, USA) For 24 hours. Then, the cells were further cultured in serum-free DMEM medium supplemented with Rg3 of Preparation Example 1 and in a serum-free DMEM medium containing no Rg3 for 48 hours.

② sebum cells: SZ95

SZ95 cells, the human sebaceous cell line, were obtained from Dr. Benjamin Franklin at the Free University of Berlin University Medical Center in Berlin, Germany. Human immortalized sebocyte (SZ95) cells from Zouboulis were cultured in a CO 2 incubator (37 ° C, 5% CO 2) using Dulbecco's modified eagle medium (DMEM) / F12 (1: 1) supplemented with 10% FBS. Then, the culture medium was changed at a cycle of 48 hours.

Experimental Example 2: Measurement of PPARs expression level

The expression levels of PPARs (PPAR-α, PPAR-β, and PPAR-γ) were measured in sebum cells cultured in Experimental Example 1 as follows. Expression level was measured by Western blotting.

First, Rg3 (20 μg / ml and 50 μg / ml) and linolenic acid (200 μg / ml) were cultured and cultured for 48 hours, respectively. Subsequently, the medium was removed and washed, and then dissolved in 80 μl of lysis buffer. The supernatant was collected by centrifugation at 4 ° C. and 12,000 rpm for 20 minutes. The amount of protein contained in the cell lysate was measured by the Bradford method. 30 [mu] l of protein was separated by SDS-PAGE containing 10% polyacrylamide and electroblotted with PVDF membrane for 1 hour at 120V. The PVDF membrane was then left in 5% skim milk for 1 hour and then placed in a primary antibody overnight at 4 ° C. After washing three times with TBST, the secondary antibody was reacted for 1 hour at room temperature, and then reacted with ECL kit (Amersham-Pharmacia) three times with TBST and quantitated using BioRad GelDoc.

RT-PCR in sebum cells is shown in Table 1, by reading the band intensities of each test value and converting the increase in content relative to the control to a percentage.

Concentration PPAR-α (%) PPAR-β (%) PPAR-γ (%) Rg3 ([mu] g / ml) 20 103.2 214.5 160.5 Rg3 ([mu] g / ml) 50 113.5 254.7 210.5 Linolenic acid (μg / ml) 200 165.4 179.5 160.5

The expression of PPAR-α, PPAR-β and PPAR-γ protein was observed after treatment with Rg3 at concentrations of 20 and 50 μg / ml for 48 hours and the expression of PPAR-β and PPAR-γ was confirmed Dependent increase in protein expression. Linolenic acid, a positive control, also increased the expression of PPAR-β and PPAR-γ.

Experimental Example 3: Measurement of expression level of SREBP-1c and FAS

The expression levels of SREBP-1c and FAS (fatty acid synthase) were measured in sebum cells cultured in Experimental Example 1 as follows. Expression level was measured by Western blotting.

First, Rg3 (20 μg / ml and 50 μg / ml) and linolenic acid (200 μg / ml) were cultured and cultured for 48 hours, respectively. Subsequently, the medium was removed and washed, and then dissolved in 80 μl of lysis buffer. The supernatant was collected by centrifugation at 4 ° C. and 12,000 rpm for 20 minutes. The amount of protein contained in the cell lysate was measured by the Bradford method. 30 μl of protein was separated by SDS-PAGE containing 10% polyacrylamide and electroblotted with PVDF membrane for 1 hour at 120V. The PVDF membrane was then left in 5% skim milk for 1 hour and then placed in a primary antibody overnight at 4 ° C. After washing three times with TBST, the secondary antibody was reacted for 1 hour at room temperature, and then reacted with ECL kit (Amersham-Pharmacia) three times with TBST and quantitated using BioRad GelDoc.

RT-PCR in sebaceous cells is shown in Table 2, by reading the band intensities of each test value and converting the increase in content relative to the control to a percentage.

Concentration SREBP-1 (%) FAS (%) Rg3 ([mu] g / ml) 20 132.5 210.4 Rg3 ([mu] g / ml) 50 186.5 224.3 Linolenic acid (μg / ml) 200 127.5 145.3

The expression of SREBP-1 and FAS (fatty acid synthase) protein was increased after treatment with Rg3 at concentrations of 20 μg / ml and 50 μg / ml for 48 h. Linolenic acid (200 μg / ml) used as a positive control also increased protein expression.

Experimental Example 4: Measurement of lipid

Lipid production was measured by nile red staining and flow cytometry.

The keratinocytes cultured in Experimental Example 1 were treated with Rg3 (20 μg / ml and 50 μg / ml) and linolenic acid 200 μg / ml, respectively, and cultured for 48 hours. The keratinocytes were harvested from each month and then stained with 1 μM Nile red solution for 10 minutes. The fluorescence intensity was measured at 552/636 (Ex / Em) nm. The measurement results are shown in Fig. 2, fluorescence intensity was measured by FACS after Nile red staining and microscopic observation revealed that lipid production was increased in the Rg3-treated group and that the cells treated with linolenic acid 200 μg / ml (87.30) (Rg 3 50 μg / ml, 95.22) with a large peak area.

Experimental Example 5: Measurement of cholesterol

SZ95 cells cultured in Experimental Example 1 were divided into 1 × 10 ⁵ cells in a 10-cm culture dish and treated with Rg3 at 25, 50, 100 and 200 μg / ml, respectively, for 5 days, and cholesterol was quantified. For cholesterol determination, the cells cultured for 5 days were treated with lysis buffer (10 μL of EDTA, 100 mM SPB solution, 1 μL of PMSF, and 10 μL of Triton X-100) and sonicated. A chloroform: methanol (2: 1) solution was added to the cell lysate, mixed and centrifuged at 2000 rpm for 15 minutes to collect the lower layer liquid and concentrate it with nitrogen gas (N ₂ ).

The concentrated sample was dissolved in 300 μL of ethanol and measured using a total cholesterol kit (AM 202-K). 100 μL of the sample was added to 1 mL of the enzyme solution, and the mixture was incubated at 37 ° C. for 5 minutes, and the absorbance was measured with an ELISA reader at a wavelength of 500 nm. Cholesterol in the standard solution was adjusted to 3 mg / mL by adding 20 μL of the standard solution to 3 mL of the enzyme solution.

The amount of cholesterol measured is shown in Table 3. Table 3 shows that the control group was 0.79 mg / ml, but in the group treated with Rg3, the cholesterol increased about twice as much as the control group.

Experimental Example 6: Measurement of triglyceride

SZ95 cells cultured in Experimental Example 1 were divided into 1 × 10 ⁵ cells in a 10-cm culture dish and treated with Rg3 at 25, 50, 100 and 200 μg / ml, respectively, for 5 days, and cholesterol was quantified. In the method for quantifying triglyceride, the cells cultured for 5 days were treated with lysis buffer (10 μL of EDTA, 100 mM SPB solution, 1 μL of PMSF, and 10 μL of Triton X-100) and disrupted by ultrasonic waves. A chloroform: methanol (2: 1) solution was added to the cell lysate, mixed and centrifuged at 2000 rpm for 15 minutes to collect the lower layer liquid and concentrate it with nitrogen gas (N ₂ ).

To the concentrated sample was added 300 ul of ethanol and dissolved, and triglyceride was measured using a triglyceride kit (GPO-PAP). 100 μL of the sample was added to 1 mL of the enzyme solution, and the mixture was incubated at 37 ° C. for 5 minutes, and the absorbance was measured with an ELISA reader at a wavelength of 546 nm. The standard solution of triglyceride was prepared by adding 20 μl of the standard solution to 3 ml of the enzyme solution to give a value of 3 mg / ml.

Formulation Example 1: Preparation of a composition containing Rg3

Formulation Examples 1, 2 and 3 (Preparation Example 1) containing Rg3 were prepared. For comparison of the efficacy, compositions (Comparative Formulation Example 1) containing glycerin and 1,3-butylene glycol as moisturizers instead of Rg3, The composition (Comparative Formulation Example 2) containing glycerin and sorbitol as a moisturizing agent and the composition (Comparative Formulation Example 3) containing neither an extract nor a moisturizer are shown in Table 4 below.

division ingredient
(Unit: wt%) Formulation Example 1 Formulation Example 2 Formulation Example 3 compare
Formulation Example compare
Formulation Example 2 compare
Formulation Example 3 A Rg3
(Production Example 1) 0.1 - - - - - Rg3
(Production Example 1) - 1.0 - - - - Rg3
(Production Example 1) - - 3.0 - - - glycerin - - - 5.0 5.0 - 1,3-butylene glycol - - - 5.0 - - Sorbitol - - - - 5.0 - EDTA-2Na 0.02 0.02 0.02 0.02 0.02 0.02 Purified water to 100 to 100 to 100 to 100 to 100 to 100 B Cetostearyl alcohol 2.0 2.0 2.0 2.0 2.0 2.0 Glyceryl stearate 1.5 1.5 1.5 1.5 1.5 1.5 Microcrystalline 0.7 0.7 0.7 0.7 0.7 0.7 Squalene 5.0 5.0 5.0 5.0 5.0 5.0 Liquid paraffin 3.0 3.0 3.0 3.0 3.0 3.0 Trioctanoin 5.0 5.0 5.0 5.0 5.0 5.0 Polysorbate 1.2 1.2 1.2 1.2 1.2 1.2 Sorbitan stearate 0.5 0.5 0.5 0.5 0.5 0.5 Tocopheryl acetate 0.2 0.2 0.2 0.2 0.2 0.2 Cyclomethicone 3.0 3.0 3.0 3.0 3.0 3.0 BHT 0.05 0.05 0.05 0.05 0.05 0.05 C Incense, preservative Suitable amount Suitable amount Suitable amount Suitable amount Suitable amount Suitable amount

Experimental Example 7: Moisturizing effect of Rg3

As intercellular lipids are produced and increased, the homeostasis, immunity and moisturizing power of the skin also increases. In order to confirm the moisturizing effect of Rg3, the clinical moisturizing effects of the compositions of Formulation Examples 1, 2 and 3 were measured as follows. A, B, and C groups were divided into five groups (A, B, C, D, and E) by a randomly selected group of 25 healthy adult men and women who felt skin dry through the questionnaire. (Comparative formulation example 1), glycerin and sorbitol as a moisturizing agent (comparative formulation example 2), a composition containing glycerin and 1,3-butylene glycol as a moisturizing agent instead of the Rg3 extract (comparative formulation example 1) Were applied to the supernumerary skin for 8 weeks twice a day, respectively. The moisturizing effect was evaluated by the Corneometer CM 820 (Corage + Khazaka, Germany) after every two weeks and after the test. The experimental results are shown in Table 6 below.

division Before use After 2 weeks of use After 4 weeks of use Formulation Example 1 23.5 33.6 43.7 Formulation Example 2 23.2 39.4 47.6 Formulation Example 3 23.2 45.8 55.4 Comparative Formulation Example 1 24.5 32.9 35.8 Comparative Formulation Example 2 22.8 33.5 36.9 Comparative Formulation Example 3 22.8 22.8 22.8

As shown in Table 6 above, it was confirmed that the moisturizing effect of Formulation Examples 1, 2 and 3 containing Rg3 of the present invention was superior to Comparative Formulation Examples 1, 2 and 3 containing other moisturizing agents.

Experimental Example 8: Measurement of ceramide

The samples of the skin keratin samples were collected using the tape method and the ceramide contents were measured under the following conditions. The content of ceramides per unit protein of the sample extracted by the tape method was determined, and the content of the protein was determined by a BSA protein assay kit.

For the ceramide analysis, UPLC-MS used Quattro Premier XE MS model connected with Waters Aquity UPLC system.

<Analysis condition>

Column: Acquity BEH C * (2.1 mm X 50 mm, 1.7 um)

Mobile phase 5 mM ammonium formate / methanol (4: 6, 0.1% formic acid)

Flow rate: 0.3 ml / min

Column temperature: 40 ° C

<MS analysis condition>

Ionization conditions-ESI cation mode

Source temperature -130 ℃

Desolvation temperature -350 ℃

Congas station 800 L / h

Capillary voltage -3.2 Kv

Ion Monitor MRM

Ceramide Formulation Example 3 (ng / mg) Comparative Formulation Example 3 (ng / mg) C16 ceramide 131.3 87.4 C18 ceramide 125.4 77.6 C24 ceramide 200.6 137.5

As a result of the test, it was confirmed that the content of the three ceramides per unit protein was increased when Formulation Example 3 and Comparative Formulation 3 were compared.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. It is therefore intended that the scope of the invention be defined by the claims appended hereto and their equivalents.

Claims (6)

A cosmetic composition for promoting skin lipid biosynthesis, which comprises ginsenoside Rg3 as an active ingredient,
Wherein the lipid is at least one selected from the group consisting of cholesterol, ceramide, and triglyceride, and the biosynthesis is carried out in keratinocytes or sebaceous cells of the skin. The method of claim 1, wherein the promoting of skin lipid biosynthesis promotes transcription factors of sterol regulatory factor binding protein (SREBP-1c), peroxisome proliferation-activating receptors (PPARs) or fatty acid synthase (FAS) A cosmetic composition for promoting lipid biosynthesis. delete delete The cosmetic composition for promoting skin lipid biosynthesis according to claim 1 or 2, wherein the ginsenoside Rg3 is contained in an amount of 0.000001 to 40.0% by weight based on the total weight of the composition. The composition of claim 1 or 2, wherein the composition is in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, cleansing oil, powder foundation, emulsion foundation, wax foundation, And spray. &Lt; RTI ID = 0.0 &gt; 11. &lt; / RTI &gt;

Images